S

Sarkis Clinical Trials | Gainesville, FL

Research site
(Unclaimed)
Location
611 NW 60th Street, Suite C, Gainesville, Florida, United States of America
Site insights

Top conditions

Depressive Disorder (25 trials)

Depression (25 trials)

Major Depressive Disorder (22 trials)

Attention Deficit Disorder with Hyperactivity (21 trials)

Hyperkinesis (19 trials)

Top treatments

SPD489
Lisdexamfetamine Dimesylate
SPD503
Rapastinel
PRC-063
Balovaptan
Aripiprazole
Lisdexamfetamine dimesylate
SEP-4199
Modafinil

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Trials

14 of 96
Status: Active
Trial type: Interventional
Funder type: Industry

Filters
3
A Study of Aticaprant 10 Milligrams (mg) as Adjunctive Therapy in Adult Participants With MDD With Moderate-to-severe Anhedonia and Inadequate Response to Current Antidepressant Therapy (VENTURA-2)

The purpose of this study is to evaluate the efficacy of aticaprant compared with placebo as adjunctive therapy to an antidepressant in improving dep...

Enrolling
Depressive Disorder, Major
Anhedonia
Other: Placebo
Drug: Aticaprant

The purpose of this study is to assess the long-term safety and tolerability of aticaprant administered as adjunctive therapy to a current antidepres...

Enrolling
Depressive Disorder, Major
Drug: Aticaprant

The purpose of this study is to assess the safety and tolerability of Seltorexant as adjunctive therapy to an antidepressant in adolescents with majo...

Enrolling
Depressive Disorder, Major
Drug: Seltorexant
Drug: Placebo

The purpose of this study is to assess the efficacy of seltorexant compared with placebo as adjunctive therapy to an antidepressant in improving depr...

Active, not recruiting
Depressive Disorder, Major
Drug: Placebo
Drug: Seltorexant

The purpose of this is study is to compare the efficacy of BHV-3500 (zavegepant) to placebo as a preventive treatment for migraine, as measured by th...

Active, not recruiting
Migraine
Drug: Placebo
Drug: BHV-3500 (zavegepant)

The primary objective of the induction phase of the study is to compare treatment retention of participants following rapid induction or standard of...

Active, not recruiting
Moderate to Severe Opioid-use Disorder
Drug: Transmucosal Buprenorphine
Drug: Extended-release Buprenorphine

The ENCALM trial is designed to evaluate the efficacy and safety of ENX-102 in patients diagnosed with generalized anxiety disorder (GAD)

Enrolling
Generalized Anxiety Disorder
Drug: Placebo
Drug: ENX-102

Migraine is a common neurological disorder typically characterized by attacks of throbbing, moderate to severe headache, often associated with nausea...

Invitation-only
Migraine
Drug: Ubrogepant

The purpose of this study is to test the long-term safety of rimegepant in the acute treatment of moderate or severe migraine in children and adolesc...

Enrolling
Acute Treatment of Migraine
Drug: Rimegepant / BHV3000

Open label, flexible dose, long-term multicenter study of safety and efficacy of SPN-812 ER in pediatric ADHD patients

Active, not recruiting
Attention-Deficit/Hyperactivity Disorder
Drug: SPN-812

The purpose of this study is to evaluate the long-term safety and tolerability of cariprazine in the treatment of pediatric participants with schizop...

Enrolling
Bipolar I Disorder
Schizophrenia
Drug: Cariprazine Flexible Dose

The purpose of this study is to test the safety and efficacy of BHV-3000 versus placebo in the acute treatment of moderate or severe migraine in chil...

Enrolling
Pediatric Migraine
Drug: Rimegepant/BHV3000
Drug: Matching placebo

Autism spectrum disorder (ASD) consists of deficits in social, communication, and cognitive development, repetitive and stereotypic behaviors. Many A...

Enrolling
Autism Spectrum Disorder
Drug: Placebo
Drug: Cariprazine

Migraine is a common neurological disorder typically characterized by attacks of throbbing, moderate to severe headache, often associated with nausea...

Enrolling
Migraine
Drug: Ubrogepant
Drug: Placebo-Matching Ubrogepant

Trial sponsors

Shire logo

Shire (17 trials)

Clinical trials

Find clinical trialsTrials by location

Resources

© Copyright 2024 Veeva Systems